278 related articles for article (PubMed ID: 16585022)
21. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
22. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
23. [Immune tolerance induction with high-dose FVIII and pulsed intravenous immunoglobulin].
Stiefel M; Pinkwart C; Haase R; Merkel N; Forsberg D; Mauz-Körholz C
Hamostaseologie; 2010 Nov; 30 Suppl 1():S119-21. PubMed ID: 21042665
[TBL] [Abstract][Full Text] [Related]
24. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
25. A review of immune tolerance induction with Haemate P in haemophilia A.
Escuriola Ettingshausen C; Kreuz W
Haemophilia; 2014 May; 20(3):333-9. PubMed ID: 24165472
[TBL] [Abstract][Full Text] [Related]
26. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
[TBL] [Abstract][Full Text] [Related]
27. What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?
Janbain M; Pipe S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):648-649. PubMed ID: 27913541
[TBL] [Abstract][Full Text] [Related]
28. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.
Antun A; Monahan PE; Manco-Johnson MJ; Callaghan MU; Kanin M; Knoll C; Carpenter SL; Davis JA; Guerrera MF; Kruse-Jarres R; Ragni MV; Witmer C; McCracken CE; Kempton CL
J Thromb Haemost; 2015 Nov; 13(11):1980-8. PubMed ID: 26382916
[TBL] [Abstract][Full Text] [Related]
29. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.
Rocino A; Papa ML; Salerno E; Capasso F; Miraglia E; de Biasi R
Haemophilia; 2001 Jan; 7(1):33-8. PubMed ID: 11136378
[TBL] [Abstract][Full Text] [Related]
30. [Immune tolerance induction in a severe hemophilia A patient with inhibitor].
Zhang L; Xue F; Liu XF; Zhou ZP; Liu YZ; Tian MS; Shen L; Xu XH; Zhang HL; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):577-80. PubMed ID: 21122314
[TBL] [Abstract][Full Text] [Related]
31. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.
Kurth M; Puetz J; Kouides P; Sanders J; Sexauer C; Bernstein J; Gruppo R; Manco-Johnson M; Neufeld EJ; Rodriguez N; Wicklund B; Quon D; Aledort L
J Thromb Haemost; 2011 Nov; 9(11):2229-34. PubMed ID: 21883884
[TBL] [Abstract][Full Text] [Related]
32. Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience.
Zulfikar B; Koc B; Ozdemir N
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e355-e358. PubMed ID: 31343592
[TBL] [Abstract][Full Text] [Related]
33. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
34. New predictive approaches for ITI treatment.
Minno GD; Santagostino E; Pratt K; Königs C
Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
[TBL] [Abstract][Full Text] [Related]
35. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.
Benson G; Auerswald G; Elezović I; Lambert T; Ljung R; Morfini M; Remor E; Salek SZ
Eur J Haematol; 2012 May; 88(5):371-9. PubMed ID: 22260405
[TBL] [Abstract][Full Text] [Related]
36. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
37. Immune tolerance induction rescue with turoctocog-alfa in a poor risk haemophilia A inhibitor young child: the history of a success.
Zanon E; Milan M; Pasca S
Blood Coagul Fibrinolysis; 2018 Jul; 29(5):465-468. PubMed ID: 29652676
[TBL] [Abstract][Full Text] [Related]
38. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
Thom K; Male C; Falger J; Pabinger I
Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
[TBL] [Abstract][Full Text] [Related]
40. Successful immune tolerance induction with a plasma-derived FVIII concentrate and intravenous immunoglobulins in a pediatric patient with congenital severe hemophilia A and poor prognostic factors.
de Cos C; Rodríguez-Martorell J
Blood Coagul Fibrinolysis; 2014 Jan; 25(1):77-80. PubMed ID: 24231694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
